Prevalence of HIV-positive test by ethnicity and region.

<p>Prevalence of HIV-positive test by ethnicity and region.</p

Patient characteristics by European region.

1<p>North:Denmark, Sweden, Netherlands, UK, West Central: Austria, Belgium, Germany, East Central: Belarus, Bosnia, Croatia, Poland, Ukraine and South: Italy and Spain.</p>2<p>IQR:Interquartile range.</p>3<p>STI: Sexually transmitted infection, LYM: Malignant lymphoma, CAN: Cervical or anal cancer/dysplasia, HZV: Herpes zoster, HEP: Hepatitis B or C, MON: Ongoing mononucleosis-like illness, CYT: Unexplained leukocytopenia/thrombocytopenia lasting >4 weeks, SEB: Seborrheic dermatitis/exanthema (SEB).</p><p>Missing data: 10 (0.3%) gender, 120 (3.3%) ethnicity, 63 (1.8%) age, 120 (3.3%) sexual orientation, 291 (8.1%) previous HIV test.</p

Prevalence of HIV by indicator condition.

*<p>Unpublished prevalence data from participating study sites.</p>**<p>includes MSM, IDU prevalence.</p>***<p>UNAIDS adults aged 15–49 country HIV prevalence rate <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052845#pone.0052845-UNAIDS2" target="_blank">[31]</a>.</p

MOESM1 of The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity

Additional file 1. Supplementary methods. Chemical synthesis process of MUT-A,HTRF®-based IN-LEDGF interaction assay, HTRF®-based IN multimerization assay, Viral RNA isolation, Northern blot analyses, primer extension assays, RT activity assays, Cryo-electron microscopy of HIV particles, Determination of HIV-1 replication capacity. Figure S1: 1H NMR spectrum of MUT-A. Figure S2: Impact of MUT-A on HIV-1 replication and production. Figure S3: Analysis of genomic RNA, Reverse transcriptase and tRNALys3 primer in MUT-A-treated HIV-1. A-D. HIV-1 RNA packaging and thermal stability of HIV-1 RNA dimers. Figure S4: HIV-1 NL4-3 particles observed by cryo-EM. A. Figure S5: Replicative capacity of HIV-1 NL4-3 viruses bearing resistance mutations to INLAIs or INSTIs. Table S1: Immunoreactivity of HIV-1 NL4-3 produced in the presence of MUT-A, or Saquinavir, or after AT2 treatment, or in the presence of DMSO. Figure S6: Results of virus immunocapture from Table S1 represented in bar graphs